Gold Stefan M, Raji Alaleh, Huitinga Inge, Wiedemann Klaus, Schulz Karl-Heinz, Heesen Christoph
Department of Neurology, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
J Neuroimmunol. 2005 Aug;165(1-2):186-91. doi: 10.1016/j.jneuroim.2005.04.014.
Clinical studies have shown that groups of multiple sclerosis (MS) patients exhibit a chronically activated hypothalamo-pituitary-adrenal (HPA) axis. However, the association of HPA axis activity and disease progression in MS is unknown. In this longitudinal study over a 3-year follow-up period, we report that patients who exhibited stronger HPA reactivity at baseline were significantly more likely to experience progression as measured by the Expanded Disability Status Scale (EDSS) during the follow-up period. Furthermore, HPA axis activity correlated with progression ratings and cognitive impairment three years later. Tests of HPA axis activity may be useful biomarkers for disease progression in MS.
临床研究表明，多发性硬化症（MS）患者群体表现出下丘脑-垂体-肾上腺（HPA）轴长期激活。然而，MS中HPA轴活性与疾病进展之间的关联尚不清楚。在这项为期3年随访期的纵向研究中，我们报告称，在随访期间，基线时表现出更强HPA反应性的患者，根据扩展残疾状态量表（EDSS）测量，其病情进展的可能性显著更高。此外，三年后HPA轴活性与病情进展评分和认知障碍相关。HPA轴活性测试可能是MS疾病进展的有用生物标志物。
